Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...
Le Lézard

Ginkgo Bioworks Awarded Project Agreement through BARDA's BioMaP-Consortium

Ginkgo Bioworks announced today that it has been awarded a contract through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium ...

Form Bio and Weill Cornell Medicine Announce Strategic Collaboration to Advance Gene Editing Therapy for Alzheimer's Disease

AI-powered vector design and preclinical validation mark the first step in a multi-phase program aimed at accelerating the path from discovery to clinical assessment in Alzheimer's disease. AUSTIN, TX ...
Santé log

Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of ...

The findings support the ongoing Phase 2 ASCEND study strategy of PCRX-201 administered at the 10-fold lower dose (1.4E11 genomic copies [GC]) with corticosteroid pretreatment.